H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
18%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Analysis of estrogen receptor (ERα and ERß) and progesterone receptor (PR) polymorphisms in uterine leiomyomas.

Francesco Massart, Lucia Becherini, Francesca Marini, Ivo Noci, Luigi Piciocchi, Francesca Del Monte, Laura Masi, Alberto Falchetti, Annalisa Tanini, Gianfranco Scarselli, Maria Luisa Brandi

Med Sci Monit 2003; 9(1): BR25-30

ID: 4788

Published: 2003-01-28


BACKGROUND: Leiomyomas are the most common tumors in women, found in up to 30% of women in active reproductive life. These tumors are estrogen- and progestin-responsive. In fact, they do not occur before menarche, undergoing rapid increase in size during pregnancy with consequent fetal wastage. Conversely, they can regress or even calcify after menopause or castration. Given the central role of sex steroids in uterus trophism, estrogen and progesterone receptors are important mediators of hormonal bioeffects, and the genes encoding these receptors become easy candidates for uterine proliferative disorders. MATERIAL/METHODS: We examined the distribution of common polymorphisms of ERa, ERb and PR genes in 413 Caucasian females: 225 post-menopausal healthy controls and 188 premenopausal women affected by uterine leiomyomas. The polymorphisms were evaluated both in constitutive and tissue DNA by PCR amplification, specific endonuclease digestion, and then detection with agarose or polyacrylamide gel electrophoresis. RESULTS: The observed allele frequencies did not deviate from the expected Hardy-Weinberg distribution in our population. In case-control analysis, no variant frequency of the studied genes differed significantly between control subjects and patients. CONCLUSIONS: Polymorphisms in the genes encoding for ERa, ERb and PR did not correlate with the occurrence of uterine leiomyomas in our Caucasian population.

Keywords: Leiomyoma - genetics



Back